Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Ce /ID# 154586
mi
from
Winston-Salem, NC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Ce /ID# 154586
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University /ID# 163822
mi
from
Portland, OR
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University /ID# 163822
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
East Penn Rheumatology Assoc /ID# 159193
mi
from
Bethlehem, PA
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
East Penn Rheumatology Assoc /ID# 159193
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
Altoona Ctr Clinical Res /ID# 154572
mi
from
Duncansville, PA
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
Altoona Ctr Clinical Res /ID# 154572
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh MC /ID# 157434
mi
from
Pittsburgh, PA
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh MC /ID# 157434
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
West Tennessee Research Inst /ID# 158721
mi
from
Jackson, TN
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
West Tennessee Research Inst /ID# 158721
mi
from
Jackson, TN
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
Adriana Pop-Moody MD Clinic PA /ID# 154607
mi
from
Corpus Christi, TX
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
Adriana Pop-Moody MD Clinic PA /ID# 154607
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
P&I Clinical Research /ID# 159191
mi
from
Lufkin, TX
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
P&I Clinical Research /ID# 159191
mi
from
Lufkin, TX
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
DM Clinical Research /ID# 158722
mi
from
Tomball, TX
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
DM Clinical Research /ID# 158722
mi
from
Tomball, TX
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
Care Access Research /ID# 158098
mi
from
Salt Lake City, UT
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
Care Access Research /ID# 158098
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated:  12/31/1969
Aprillus Asistencia e Investig /ID# 159173
mi
from
Capital Federal,
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Enrolling
Updated: 12/31/1969
Aprillus Asistencia e Investig /ID# 159173
mi
from
Capital Federal,
Click here to add this to my saved trials
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated:  12/31/1969
Barrington Orthopedic Specialissts
mi
from
Schaumburg, IL
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated: 12/31/1969
Barrington Orthopedic Specialissts
mi
from
Schaumburg, IL
Click here to add this to my saved trials
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated:  12/31/1969
Joint Implant Surgeons, Inc.
mi
from
New Albany, OH
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated: 12/31/1969
Joint Implant Surgeons, Inc.
mi
from
New Albany, OH
Click here to add this to my saved trials
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated:  12/31/1969
Mid-South Orthopedic Associates
mi
from
Cordova, TN
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated: 12/31/1969
Mid-South Orthopedic Associates
mi
from
Cordova, TN
Click here to add this to my saved trials
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated:  12/31/1969
Texas Orthopedic Specialist
mi
from
Bedford, TX
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated: 12/31/1969
Texas Orthopedic Specialist
mi
from
Bedford, TX
Click here to add this to my saved trials
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated:  12/31/1969
Texas Center for Joint Replacement
mi
from
Plano, TX
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated: 12/31/1969
Texas Center for Joint Replacement
mi
from
Plano, TX
Click here to add this to my saved trials
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated:  12/31/1969
Advanced Orthopaedic Centers
mi
from
Richmond, VA
A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System
A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System
Status: Enrolling
Updated: 12/31/1969
Advanced Orthopaedic Centers
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates, PC
mi
from
Birmingham, AL
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Connecticut
mi
from
Danbury, CT
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Connecticut
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Arthritis Consultants
mi
from
Saint Louis, MO
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Arthritis Consultants
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Arthritis and Osteoporosis Associates
mi
from
Freehold, NJ
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Arthritis and Osteoporosis Associates
mi
from
Freehold, NJ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated:  12/31/1969
Barwon Rheumatology Services
mi
from
Geelong,
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status: Enrolling
Updated: 12/31/1969
Barwon Rheumatology Services
mi
from
Geelong,
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates, PC
mi
from
Birmingham, AL
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Connecticut
mi
from
Danbury, CT
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Connecticut
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Consultants
mi
from
Saint Louis, MO
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Consultants
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Multiprofile Hospital for Active Treatment - Plovdiv
mi
from
Plovdiv,
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Multiprofile Hospital for Active Treatment - Plovdiv
mi
from
Plovdiv,
Click here to add this to my saved trials
Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management
Comparison Between Cooled (C-RFA) and Standard (t-RFA) Radiofrequency Ablation, and Control for Pain Management Following Unilateral Knee Arthroplasty: A Double-Blinded, Parallel-Grouped, Placebo-Controlled Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Orthopedic Specialty Institute
mi
from
Coeur d'Alene, ID
Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management
Comparison Between Cooled (C-RFA) and Standard (t-RFA) Radiofrequency Ablation, and Control for Pain Management Following Unilateral Knee Arthroplasty: A Double-Blinded, Parallel-Grouped, Placebo-Controlled Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Orthopedic Specialty Institute
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management
Comparison Between Cooled (C-RFA) and Standard (t-RFA) Radiofrequency Ablation, and Control for Pain Management Following Unilateral Knee Arthroplasty: A Double-Blinded, Parallel-Grouped, Placebo-Controlled Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Orthopedic Specialty Institute
mi
from
Spokane, WA
Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management
Comparison Between Cooled (C-RFA) and Standard (t-RFA) Radiofrequency Ablation, and Control for Pain Management Following Unilateral Knee Arthroplasty: A Double-Blinded, Parallel-Grouped, Placebo-Controlled Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Orthopedic Specialty Institute
mi
from
Spokane, WA
Click here to add this to my saved trials
Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee
Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee: Effect on Pain and Quality of Life
Status: Enrolling
Updated:  12/31/1969
McConnell Spine, Sport, and Joint Physicians
mi
from
Columbus, OH
Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee
Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee: Effect on Pain and Quality of Life
Status: Enrolling
Updated: 12/31/1969
McConnell Spine, Sport, and Joint Physicians
mi
from
Columbus, OH
Click here to add this to my saved trials
ReNu™ Injection to Treat Hip Osteoarthritis Study
A Pilot Study of ReNu™ Hip Injection: Monitoring the Response of Hip Function and Pain in Patient With Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
Stanford Medicine Orthopaedic Surgery
mi
from
Redwood City, CA
ReNu™ Injection to Treat Hip Osteoarthritis Study
A Pilot Study of ReNu™ Hip Injection: Monitoring the Response of Hip Function and Pain in Patient With Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
Stanford Medicine Orthopaedic Surgery
mi
from
Redwood City, CA
Click here to add this to my saved trials
ReNu™ Injection to Treat Hip Osteoarthritis Study
A Pilot Study of ReNu™ Hip Injection: Monitoring the Response of Hip Function and Pain in Patient With Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
ReNu™ Injection to Treat Hip Osteoarthritis Study
A Pilot Study of ReNu™ Hip Injection: Monitoring the Response of Hip Function and Pain in Patient With Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated:  12/31/1969
St. Vincent Charity Medical Center
mi
from
Cleveland, OH
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated: 12/31/1969
St. Vincent Charity Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Houston Methodist West Hospital
mi
from
Houston, TX
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Houston Methodist West Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated:  12/31/1969
St. Francis Hospital
mi
from
New York, NY
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated: 12/31/1969
St. Francis Hospital
mi
from
New York, NY
Click here to add this to my saved trials
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated:  12/31/1969
North Carolina Specialty Hospital
mi
from
Durham, NC
TSolution One® Total Knee Arthroplasty
TSolution One® Total Knee Arthroplasty Clinical Trial
Status: Enrolling
Updated: 12/31/1969
North Carolina Specialty Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty
Psoas Compartment Block Versus Periarticular Local Anesthetic Infiltration for Pain Management for Total Hip Arthroplasty: A Prospective, Randomized Study
Status: Enrolling
Updated:  12/31/1969
Beaumont Hospital
mi
from
Royal Oak, MI
Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty
Psoas Compartment Block Versus Periarticular Local Anesthetic Infiltration for Pain Management for Total Hip Arthroplasty: A Prospective, Randomized Study
Status: Enrolling
Updated: 12/31/1969
Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls
Status: Enrolling
Updated:  12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls
Status: Enrolling
Updated: 12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials